← Leaderboards
Jeffrey Schlom
Basic Sciences
$0
Attributed
$0
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 1
By mechanism
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Basic Sciences
Same institution · by research overlap
- James L. Gulley$1,096,273
- Philip M Arlen$0
- Jeffrey S Rubin$0
Others in their field
Top investigators on “Tumor Antigens”
- William R Green · Dartmouth College$32,738,211
- John H Sampson · Duke University$30,849,602
- Catherine Ju-Ying Wu · Broad Institute, Inc.$30,485,072
- Elizabeth Marion Jaffee · Johns Hopkins University$26,862,085
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$24,066,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Tumor AntigensImmuneVaccinesImmune ResponseTumorT-LymphocyteResponseCellsNeoplastic CellImmunotherapeutic AgentCancer ImmunotherapyClinical ResearchRecombinantsCd8b1 GeneMalignant NeoplasmsClinical TrialsBaseImmunotherapyCancer PatientCarcinomaMediatingDesignCytokineCombined Modality Therapy
Grant awards (89)
Strategies for Cancer Immunotherapy Development: Preclinical Studies$3,580,727
ZIA · FY2025 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$2,387,152
ZIA · FY2025 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$4,095,431
ZIA · FY2024 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,755,184
ZIA · FY2024 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$3,837,391
ZIA · FY2023 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,918,695
ZIA · FY2023 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$639,565
ZIA · FY2023 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$2,088,156
ZIA · FY2022 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,566,117
ZIA · FY2022 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$1,566,117
ZIA · FY2022 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$2,125,238
ZIA · FY2021 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,593,930
ZIA · FY2021 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$1,593,930
ZIA · FY2021 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$2,028,388
ZIA · FY2020 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,521,291
ZIA · FY2020 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$1,521,291
ZIA · FY2020 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$1,535,915
ZIA · FY2019 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$1,151,937
ZIA · FY2019 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,151,937
ZIA · FY2019 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$1,477,130
ZIA · FY2018 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$1,107,849
ZIA · FY2018 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,107,849
ZIA · FY2018 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$1,477,304
ZIA · FY2017 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$1,107,978
ZIA · FY2017 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$1,107,978
ZIA · FY2017 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$779,653
ZIA · FY2016 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$584,740
ZIA · FY2016 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$584,740
ZIA · FY2016 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Immunotherapy$845,528
ZIA · FY2015 · CA · contact PI
Strategies for Cancer Immunotherapy Development: Preclinical Studies$634,145
ZIA · FY2015 · CA · contact PI
Strategies for Cancer Immunotherapy Clinical Trials$634,145
ZIA · FY2015 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Vaccine Development$852,537
ZIA · FY2014 · CA · contact PI
Strategies for Therapeutic Cancer Vaccine Clinical Trials$639,402
ZIA · FY2014 · CA · contact PI
Strategies for Cancer Vaccine Development: Preclinical Studies$639,402
ZIA · FY2014 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Vaccine Development$755,122
ZIA · FY2013 · CA · contact PI
Strategies for Cancer Vaccine Development: Preclinical Studies$566,341
ZIA · FY2013 · CA · contact PI
Strategies for Therapeutic Cancer Vaccine Clinical Trials$566,341
ZIA · FY2013 · CA · contact PI
Strategies for Therapeutic Cancer Vaccine Clinical Trials$816,925
ZIA · FY2012 · CA · contact PI
Strategies for Cancer Vaccine Development: Preclinical Studies$612,693
ZIA · FY2012 · CA · contact PI
Human Immune Responses to Tumor Antigens for Cancer Vaccine Development$612,693
ZIA · FY2012 · CA · contact PI
Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials$891,242
ZIA · FY2011 · CA · contact PI
Control of the immune response for cancer vaccine development$668,432
ZIA · FY2011 · CA · contact PI
Human T Cell Responses to Tumor Antigens for Cancer Vaccine Development$668,432
ZIA · FY2011 · CA · contact PI
Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials$387,966
ZIA · FY2010 · CA · contact PI
Human T Cell Responses to Tumor Antigens for Cancer Vaccine Development$290,975
ZIA · FY2010 · CA · contact PI
Control of the immune response for cancer vaccine development$290,975
ZIA · FY2010 · CA · contact PI
Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials$538,509
ZIA · FY2009 · CA · contact PI
Human T Cell Responses to Tumor Antigens for Cancer Vaccine Development$403,882
ZIA · FY2009 · CA · contact PI
Control of the immune response for cancer vaccine development$403,882
ZIA · FY2009 · CA · contact PI
Analysis of Human Immune Reponses in Cancer Vaccine Clinical Trials$650,466
Z01 · FY2008 · CA · contact PI
Novel Targets for Vaccine Therapy$541,259
Z01 · FY2008 · CA · contact PI
Human T Cell Responses to Tumor Antigens for Cancer Vaccine Development$433,644
Z01 · FY2008 · CA · contact PI
Control of the immune response for cancer vaccine development$361,370
Z01 · FY2008 · CA · contact PI
Development of Novel Vaccine Strategies$2,453,605
Z01 · FY2007 · CA · contact PI
Human T-Cell Responses to Tumor Antigens$2,027,509
Z01 · FY2007 · CA · contact PI
Development of Novel Vaccine Strategies$0
Z01 · FY2006 · BC · contact PI
Human T-Cell Responses to Tumor Antigens$0
Z01 · FY2006 · BC · contact PI
Development of Novel Vaccine Strategies$0
Z01 · FY2005 · BC
Human T-Cell Responses to Tumor Antigens$0
Z01 · FY2005 · BC
Vaccine Clinical Trials$0
Z01 · FY2005 · BC
Mechanism of Human T-Cell Activation$0
Z01 · FY2005 · BC
Novel Recombinant Immunoglobulin Forms for Cancer Therap$0
Z01 · FY2005 · BC
Cytokines as Biologic Adjuvants$0
Z01 · FY2005 · BC
Mechanism of Human T-Cell Activation$0
Z01 · FY2004 · BC
Human T-Cell Responses to Tumor Antigens$0
Z01 · FY2004 · BC
Novel Recombinant Immunoglobulin Forms for Cancer Therap$0
Z01 · FY2004 · BC
The Use of Cancer Vaccines and Combination Therapies$0
Z01 · FY2004 · BC
T-Cell Costimulation in Design of Cancer Vaccines$0
Z01 · FY2003 · BC
Cytokines as Biologic Adjuvants$0
Z01 · FY2003 · BC
Development of Vaccines and Vaccine Strategies for Human$0
Z01 · FY2003 · BC
Design and Development of Novel Immunotherapeutics$0
Z01 · FY2003 · BC
Development of Vaccines and Vaccine Strategies for Human$0
Z01 · FY2002 · BC
Design and Development of Novel Immunotherapeutics and S$0
Z01 · FY2002 · BC
CEA VACCINIA VIRUS W/ POST VACCINATION CEA PEPTIDE BOOST$0
M01 · FY2002 · RR
Design and Development of Novel Immunotherapeutics$0
Z01 · FY2001 · BC
T-Cell Costimulation in the Design of Cancer Vaccines$0
Z01 · FY2001 · BC
CEA VACCINIA VIRUS W/ POST VACCINATION CEA PEPTIDE BOOST$0
M01 · FY2001 · RR
Mechanism of Human T-Cell Activation$0
Z01 · FY2001 · BC
Vaccines /Vaccine Strategies for Human Cancer$0
Z01 · FY2001 · BC
CEA VACCINIA VIRUS W/ POST VACCINATION CEA PEPTIDE BOOST$0
M01 · FY2001 · RR
Recombinant Immunoglobulin Forms--Cancer Therapy /Diagn.$0
Z01 · FY2001 · BC
CEA VACCINIA VIRUS W/ POST VACCINATION CEA PEPTIDE BOOST$0
M01 · FY2001 · RR
Cytokines as Biologic Adjuvants$0
Z01 · FY2001 · BC
T- CELL COSTIMULATION IN THE DESIGN OF CANCER VACCINES$0
Z01 · FY2000 · BC
MECHANISM OF HUMAN T-CELL ACTIVATION$0
Z01 · FY2000 · BC
RECOMBINANT IMMUNOGLOBULIN FOR CA THERAPY &DIAGNOSIS$0
Z01 · FY2000 · BC
CYTOKINES AS BIOLOGIC ADJUVANTS$0
Z01 · FY2000 · BC
Design and Development of Novel Immunotherapies for Human Cancer$0
Z01 · FY2000 · BC
DEVELOPMENT OF VACCINES &VACCINE STRATEGIES FOR CANCER$0
Z01 · FY2000 · BC